Switch theme
Sign up to access all valuation multiples
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
1996
75.9K+
LTM Revenue $45.3B
LTM EBITDA $18.5B
$244B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novartis has a last 12-month revenue of $45.3B and a last 12-month EBITDA of $18.5B.
In the most recent fiscal year, Novartis achieved revenue of $62.1B and an EBITDA of $24.9B.
Novartis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novartis valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $45.3B | XXX | XXX | XXX | XXX |
| Gross Profit | $35.5B | XXX | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | XXX | XXX | XXX |
| EBITDA | $18.5B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | XXX | XXX | XXX |
| EBIT | $17.6B | XXX | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | XXX | XXX | XXX |
| Net Profit | $14.2B | XXX | XXX | XXX | XXX |
| Net Margin | 31% | XXX | XXX | XXX | XXX |
| Net Debt | $21.6B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novartis's stock price is CHF 93 (or $111).
Novartis has current market cap of CHF 183B (or $220B), and EV of CHF 203B (or $244B).
See Novartis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $244B | $220B | XXX | XXX | XXX | XXX | $8.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novartis has market cap of $220B and EV of $244B.
Novartis's trades at 4.5x EV/LTM Revenue multiple, and 11.0x EV/LTM EBITDA.
Equity research analysts estimate Novartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novartis has a P/E ratio of 12.9x.
See valuation multiples for Novartis and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $220B | XXX | XXX | XXX | XXX |
| EV (current) | $244B | XXX | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | XXX | XXX | XXX |
| EV/EBIT | 11.5x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | XXX | XXX | XXX |
| P/E | 12.9x | XXX | XXX | XXX | XXX |
| EV/FCF | 14.8x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovartis's last 12 month revenue growth is 0%
Novartis's revenue per employee for the last 12 months averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Novartis's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novartis's rule of X is 40% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novartis and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novartis acquired XXX companies to date.
Last acquisition by Novartis was XXXXXXXX, XXXXX XXXXX XXXXXX . Novartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novartis founded? | Novartis was founded in 1996. |
| Where is Novartis headquartered? | Novartis is headquartered in Switzerland. |
| How many employees does Novartis have? | As of today, Novartis has 75.9K+ employees. |
| Who is the CEO of Novartis? | Novartis's CEO is Dr. Vasant Narasimhan. |
| Is Novartis publicy listed? | Yes, Novartis is a public company listed on SWX. |
| What is the stock symbol of Novartis? | Novartis trades under NOVN ticker. |
| When did Novartis go public? | Novartis went public in 2001. |
| Who are competitors of Novartis? | Similar companies to Novartis include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Novartis? | Novartis's current market cap is $220B |
| What is the current revenue of Novartis? | Novartis's last 12 months revenue is $45.3B. |
| What is the current revenue growth of Novartis? | Novartis revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Novartis? | Current revenue multiple of Novartis is 4.5x. |
| Is Novartis profitable? | Yes, Novartis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novartis? | Novartis's last 12 months EBITDA is $18.5B. |
| What is Novartis's EBITDA margin? | Novartis's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Novartis? | Current EBITDA multiple of Novartis is 11.0x. |
| What is the current FCF of Novartis? | Novartis's last 12 months FCF is $13.7B. |
| What is Novartis's FCF margin? | Novartis's last 12 months FCF margin is 30%. |
| What is the current EV/FCF multiple of Novartis? | Current FCF multiple of Novartis is 14.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
